PT-141: A Melanocortin Peptide With an Unusual History
PT-141 is a good reminder that research rarely goes where it intends to. It began as a tanning study and ended somewhere else entirely.
Some compounds are designed to do one thing and discovered to do another. PT-141 is the standard example, and the story is worth telling because it explains the chemistry.
From tanning research to the central nervous system
The melanocortin system is a family of receptors, MC1R through MC5R, activated by peptides derived from proopiomelanocortin. MC1R governs pigmentation, which is what researchers were originally chasing when they developed synthetic analogues of alpha-melanocyte stimulating hormone.
During that programme, effects unrelated to pigmentation were observed. Follow-up work traced them to central melanocortin receptors — MC3R and MC4R in particular, which sit in the hypothalamus and are involved in appetite, energy balance and sexual signalling. PT-141, also known as bremelanotide, came out of that redirection: a cyclic heptapeptide with reduced pigmentation activity and retained central activity.
Why cyclic matters
PT-141 is a cyclic peptide — the chain is closed into a ring. Cyclisation locks the molecule into a defined shape, which improves receptor selectivity and makes it far harder for exopeptidases to chew it from the ends. That structural detail is a large part of why it behaves differently from the linear peptide it descended from.
The clinical record
Bremelanotide went through formal clinical development and holds regulatory approval in some jurisdictions for a specific, narrowly defined indication in women, under prescription. Trial publications describe both the measured endpoints and the adverse-effect profile, including transient blood pressure changes and nausea.
Research-grade PT-141 is not the approved medicine and is not for human use. An approval elsewhere does not transfer to laboratory material, and nothing here is medical guidance.
Research directions
- Melanocortin receptor selectivity and binding studies.
- Central nervous system signalling and hypothalamic pathway work.
- Appetite and energy-balance research through MC4R.
- Comparative studies against linear melanocortin analogues.
Handling
Cyclic peptides are generally more robust than linear ones, but the usual rules still apply: cold, dark, dry storage for the lyophilised powder; gentle reconstitution; refrigerated, dated working solutions. Because MC4R work is dose-sensitive in cell assays, accurate reconstitution volumes matter more here than in many protocols — measure, do not estimate.
Related products
See allFrequently asked questions
What is the difference between PT-141 and bremelanotide?
They are the same molecule. PT-141 is the development code; bremelanotide is the international non-proprietary name.
Why did it come out of tanning research?
It descends from alpha-MSH analogues developed for pigmentation research, where unrelated central effects were observed and followed up.
Is research material the same as the approved product?
No. Approved medicines are manufactured, formulated and released under pharmaceutical regulation. Research material is not a medicine.
Sources and further reading
About the author
Synedica Research Desk
Scientific content team
The Synedica Research Desk writes and maintains the technical library behind the Synedica Europe catalogue. The team compiles publicly available literature, supplier documentation and analytical data into plain-language explainers for laboratory and research audiences.
- Reviews certificates of analysis supplied with every Synedica batch
- Sources claims from peer-reviewed literature and regulator publications
- Publishes review dates and correction notes on every article
Continue reading
See all
Thymosin Alpha-1: The Immunology Reference Peptide
Of the ten compounds in this series, thymosin alpha-1 has the longest and most conventional research history. It is a useful benchmark for the rest.
BPC-157: What the Literature Actually Describes
Fifteen amino acids, an unusually stable structure and a very large preclinical literature. Here is what BPC-157 is, and what the published work does and does not show.
Avoiding Contamination on the Bench
Contamination rarely announces itself. It shows up later as an unexplained result — which is why technique is cheaper than repeating the work.